Genflow Biosciences Plc (GB:GENF) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Genflow Biosciences Plc has secured €4 million in non-dilutive funding from the Wallonia region to advance its gene therapy, GF-1002, aimed at treating Metabolic Associated Steatohepatitis (MASH). This financial boost includes a research grant and a repayable advance, covering substantial development costs and marking a significant step forward for the company. The support underscores the innovation and potential of Genflow’s approach in an area with limited treatment options.
For further insights into GB:GENF stock, check out TipRanks’ Stock Analysis page.
